Ramky Infra Board OKs Visakha Pharmacity Stake Sale to BGCCPL

INDUSTRIAL-GOODSSERVICES
Whalesbook Corporate News Logo
AuthorKavya Nair|Published at:
Ramky Infra Board OKs Visakha Pharmacity Stake Sale to BGCCPL
Overview

Ramky Infrastructure Limited's Board of Directors has approved selling its stake in Visakha Pharmacity Limited (VPCL) to Brij Gopal Construction Company Private Limited (BGCCPL). This sale, already backed by shareholders, is a move to streamline the company's assets, with senior management set to finalize the Share Purchase Agreement.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

Ramky Infra Board Approves Visakha Pharmacity Stake Sale to BGCCPL

The Board of Directors of Ramky Infrastructure Limited has officially approved the sale of its stake in Visakha Pharmacity Limited (VPCL) to Brij Gopal Construction Company Private Limited (BGCCPL). The company's senior management, including the Managing Director and CFO, has been authorized to finalize the specific terms of the Share Purchase Agreement (SPA).

Shareholder Nod Paved the Way

This board decision, formalized during a meeting held on March 28, 2026, builds upon prior shareholder consent for the transaction. Ramky Infrastructure had previously secured approval from its members via a postal ballot, with notice issued on December 27, 2023, and results declared on January 28, 2024.

Strategic Move to Streamline Operations

The divestment of Visakha Pharmacity is a key part of Ramky Infrastructure's strategy to streamline its business operations and concentrate capital on its core infrastructure development and construction activities. By exiting this stake, the company aims to enhance its resource allocation towards its primary engineering, procurement, and construction (EPC) and infrastructure development segments.

Expected Outcomes of the Divestment

Following the completion of the sale, Ramky Infrastructure will no longer hold a stake in Visakha Pharmacity Limited. The transaction is expected to generate capital for the company, which could be utilized for debt reduction or reinvestment in key projects. This move will further sharpen the company's focus on its main business areas.

Past Challenges and Sale Contingencies

While approvals are now in place, the actual completion of the sale hinges on the finalization of the Share Purchase Agreement. Investors will also note Ramky Infrastructure's financial history, which includes corporate debt restructuring (CDR) around 2013-2014. This past experience highlights the ongoing importance of effective asset management and capital allocation for the company.

Industry-Wide Divestment Trend

Strategic divestments of non-core assets are a common practice within the Indian infrastructure sector. Major firms like IRB Infrastructure Developers, Dilip Buildcon, and GMR Infrastructure also periodically sell stakes in subsidiaries or special purpose vehicles. This approach helps these companies optimize their balance sheets and concentrate resources on core construction and development.

What to Watch For Next

Key developments to monitor include the final execution of the SPA between Ramky Infra and BGCCPL, confirmation of the sale proceeds, and their subsequent deployment by Ramky Infrastructure. Further, any disclosures required by SEBI LODR Regulations post-SPA signing will be important, as will management's commentary on how this divestment aligns with the company's future strategic direction.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.